Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma-Reference-Cited by-同舟云学术

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

Published:2004-10 Issue:10 Volume:10 Page:698-708
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Kröger Nicolaus,Perez-Simon Jose A.,Myint Han,Klingemann Hans,Shimoni Avichai,Nagler Arnon,Martino Rodrigo,Alegre Adrian,Tomas Jose F.,Schwerdtfeger Rainer,Kiehl Michael,Fauser Axel,Sayer Herbert Gottfried,Leon Angel,Beyer Jörg,Zabelina Tatjana,Ayuk Francis,San Miguel Jesus F.,Brand Ronald,Zander Axel Rolf

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference22 articles.

1. Allogeneic marrow transplantation for multiple myeloma;Bensinger;Blood,1996

2. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma;Bjorkstrand;Blood,1996

3. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma;Gahrton;J Clin Oncol,1995

4. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM);Kroger;Bone Marrow Transplant,2003

5. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma;Majolino;Bone Marrow Transplant,1998

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect;Hemato;2021-04-14

2. Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma;Biology of Blood and Marrow Transplantation;2020-08

3. Development of CAR-T cell therapies for multiple myeloma;Leukemia;2020-06-22

4. Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation;Bone Marrow Transplantation;2019-09-24

5. Therapie des rezidivierten und refraktären multiplen Myeloms;Der Onkologe;2018-03-21